Thom Frielink | Sr. Associate
Curie Capital BV

Thom Frielink is a seasoned professional in the field of orphan drugs, currently serving as a Senior Associate at Curie Capital BV. With a strong background in healthcare and pharmaceuticals, Thom brings a wealth of experience in strategy development, advocacy, and partnership building within the orphan drug industry.

Throughout his career, Thom has demonstrated a deep commitment to improving access to life-saving treatments for rare diseases. His strategic mindset and collaborative approach have enabled him to drive impactful initiatives that address the unique challenges faced by patients with rare conditions.

Thom's expertise lies in identifying innovative solutions to complex problems, forging partnerships with key stakeholders, and advocating for policies that support the orphan drug ecosystem. His dedication to making a difference in the lives of patients has earned him a reputation as a trusted leader in the field.

At Curie Capital BV, Thom plays a pivotal role in shaping the company's investment strategies in the orphan drug space. He leverages his industry knowledge and network to identify promising opportunities for growth and impact, ultimately contributing to the advancement of orphan drug development and access.

Thom Frielink is a dynamic professional who is passionate about driving positive change in the orphan drug industry. With his strategic vision and commitment to collaboration, he continues to be a driving force in advancing the field and improving outcomes for patients with rare diseases.